



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 June 2015
EMA/CHMP/357351/2015
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (initial authorisation)

Pregabalin Accord

pregabalin

On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pregabalin Accord, intended for the treatment of epilepsy and generalised anxiety disorder. The applicant for this medicinal product is Accord Healthcare Limited.

Pregabalin Accord will be available as 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg hard capsules. The active substance of Pregabalin Accord is pregabalin, a gamma-aminobutyric acid (GABA) analogue (ATC code N03AX16). Pregabalin modulates neuronal excitability in the central nervous system.

Pregabalin Accord is a generic of Lyrica, which has been authorised in the EU since 6 June 2004. Studies have demonstrated the satisfactory quality of Pregabalin Accord, and its bioequivalence to the reference product Lyrica. A question and answer document on generic medicines can be found [here](#).

The full indication is:

Epilepsy

Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised Anxiety Disorder

Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.”

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

